Latest News

Amid ongoing global market volatility driven by Middle East tensions and energy market fluctuations, Asian markets have been navigating a complex landscape. For investors exploring opportunities beyond the mainstream, penny stocks—often representing smaller or newer companies—remain an intriguing option. While the term may seem dated, these stocks can offer a blend of affordability and growth potential when backed by strong financials.

It looks like Omer-Decugis & Cie SA ( EPA:ALODC ) is about to go ex-dividend in the next three days. Typically, the...

Atreyu Capital Markets Ltd ( TLV:ATRY ) stock is about to trade ex-dividend in three days. Typically, the ex-dividend...

Amidst ongoing geopolitical tensions and energy market volatility, Asian markets are navigating a complex landscape with mixed signals from global indices. As investors seek stability in uncertain times, dividend stocks offer an attractive proposition for their potential to provide consistent income streams. Identifying strong dividend stocks requires a focus on companies with solid financial health and the ability to sustain payouts even during economic fluctuations.

If you are wondering whether Tyler Technologies is starting to look attractively priced after a tough run, the recent share performance gives you plenty to think about. At a last close of US$327.88, the stock has recorded a 1.7% decline over the past 7 days, a 10.7% decline over 30 days, a 24.8% decline year to date, and a 42.0% decline over the past year. These moves have kept Tyler Technologies on the radar for investors who focus on quality software names that have come under pressure...

If you are wondering whether KB Home at around US$51.41 is priced attractively or not, the key is to look closely at what the current share price implies about the business. The stock has been relatively flat over the last week with a 0.4% return, but the 10.4% decline over the past 30 days and the 9.9% decline year to date sit against a longer 3 year return of 37.7% and 5 year return of 15.2%. Those mixed returns come as investors continue to weigh sector sentiment and broader housing...

KKR (KKR) shares have been reacting to news that the firm was selected alongside Carlyle to help the US Army build and operate a large AI capable data centre on a military base. See our latest analysis for KKR. The US Army data centre decision comes after a mixed run for KKR, with a 3.54% 1 day share price return and a 2.85% 7 day share price return contrasting with a 90 day share price decline of 29.69%. At the same time, the 3 year total shareholder return of 87.32% shows how different...

Analyst upgrade puts Heritage Financial (HFWA) back on investor radar Investment analysts at Wall Street Zen have shifted Heritage Financial (HFWA) from a sell rating to a hold rating, citing recent financial results and the bank's position in the Pacific Northwest as key factors. See our latest analysis for Heritage Financial. Heritage Financial's recent upgrade comes against a backdrop of building momentum, with a 1 month share price return of 8.81% and a 1 year total shareholder return of...

If you are wondering whether Wendy's current share price really reflects what the business is worth, this breakdown will help you connect the recent moves in the stock to what the underlying valuation signals are saying. The share price recently closed at US$7.06, with returns of 2.3% over 7 days, a 2.9% decline over 30 days, a 13.6% decline year to date, and a 42.8% decline over the past year, which may have shifted how investors view both risk and potential upside. Recent coverage around...

Land & Buildings has escalated its activist campaign at First Industrial Realty Trust (NYSE:FR), urging shareholders to vote against the re-election of the current Chairman and a long-serving director at the upcoming annual meeting. The activist investor argues that recent actions by FR, including a share buyback, dividend increase, and addition of a new director, do not fully address what it views as ongoing governance and valuation concerns. Land & Buildings is calling for substantial...

Amtagvi data and pipeline momentum reshape the story for Iovance Biotherapeutics (IOVA) The latest move in Iovance Biotherapeutics (IOVA) has been driven by real world data for its Amtagvi cell therapy that outperformed pivotal trial results, together with growing attention on upcoming NSCLC data and wider pipeline progress. See our latest analysis for Iovance Biotherapeutics. At a share price of $3.47, Iovance has seen a 4.52% 1 day share price return and 37.70% year to date share price...

Siemens (XTRA:SIE) is back in focus after its mobility arm joined the Quebec Connexion Capitale consortium, which was recently selected to deliver systems for the Québec City tramway project, alongside rising interest in Siemens backed digital twin solutions. See our latest analysis for Siemens. The latest contract win and ongoing interest in Siemens backed digital twin solutions come at a time when the shares trade at €231.5, with a 1 day share price return of 10.24% and a 1 year total...

Why the Sangdong start-up matters for Almonty Industries (TSX:AII) Almonty Industries (TSX:AII) is drawing fresh attention after announcing the official start of operations at its redeveloped Sangdong tungsten mine in South Korea, backed by long-term offtake agreements for US defense applications. See our latest analysis for Almonty Industries. The Sangdong launch appears to have sharpened market attention, with a 9.53% 1 day share price return and 16.55% 7 day share price return lifting...

If you are wondering whether Biogen's current share price reflects its true worth, you are not alone. Many investors are asking whether the stock still offers value after its recent moves. The stock last closed at US$179.90, with a 1 year return of 49.3% but also shorter term moves of a 2.1% decline over 7 days, a 4.4% decline over 30 days, and a modest 1.2% gain year to date. These shifts can change how the market views both its growth potential and risk. Recent news flow around Biogen has...

If you are asking whether Rio Tinto Group is still fairly priced after its recent run, this article walks through the numbers so you can judge the value for yourself. The stock last closed at £73.32, with returns of 3.0% over 7 days, 10.5% over 30 days, 22.5% year to date and 87.3% over 1 year. These performance figures naturally raise questions about what is already reflected in the price. Recent attention on Rio Tinto Group has focused on its position in global materials markets and how...

IREN (NasdaqGS:IREN) is back in focus after its multi billion dollar AI cloud agreements, including a five year deal with Microsoft, sharpened investor attention on the company’s pivot away from Bitcoin mining. See our latest analysis for IREN. After concerns around the US$6b at-the-market equity program and execution risks in its AI pivot led to a roughly 20% slide over a recent five-session stretch, the latest multi billion dollar AI cloud contracts and GPU purchase updates have coincided...

Wondering whether PTC at around US$144 per share offers real value or just noise? This article walks through what the current price may be implying about the business. The stock is up 1.3% over the last 7 days, even though it shows a 11.7% decline over 30 days and a 15.2% decline year to date, with a 3.3% decline over the past year and a 14.2% return over three years. These mixed returns put extra focus on what has been moving sentiment around PTC recently, as investors react to new...

Paramount Skydance has secured $24b in equity funding from Middle Eastern sovereign wealth funds for its planned acquisition of Warner Bros. Discovery (NasdaqGS:WBD). The commitments come from Saudi Arabia's Public Investment Fund, Qatar Investment Authority, and Abu Dhabi's L’imad Holding. A special shareholder meeting and ongoing regulatory reviews are the next milestones for the proposed takeover of WBD. Warner Bros. Discovery, the combined media and entertainment group behind Warner...

Morgan Stanley (NYSE:MS) has launched MSBT, a spot Bitcoin ETF that it issues directly as a major US bank. The ETF carries a 0.14% fee, which is lower than many existing spot Bitcoin ETFs in the US market. The launch expands Morgan Stanley's digital asset offerings, alongside filings for Solana and Ethereum trusts and plans for direct crypto trading. Morgan Stanley, a large US bank and wealth manager, is moving deeper into digital assets with MSBT, a proprietary spot Bitcoin ETF. For...

If you are wondering whether Medtronic at around US$88.65 is a bargain or just fairly priced, you are in the right place for a clear look at what the numbers are saying about its value. The share price has returned 3.0% over the last week, with a 2.9% decline over the past month, a 7.7% decline year to date, a 7.3% return over 1 year, a 20.9% return over 3 years, and a 16.6% decline over 5 years. Taken together, this gives you a mixed picture of recent gains and longer term swings in...

Wondering whether Equifax at US$184.38 is starting to look interesting on price, or if there is a better entry point? This article walks through what the current market value really reflects. The stock has recently shown mixed performance, with a 2.6% move over the past week, a 9.9% decline over 30 days, and returns of 13.9% lower year to date and 17.1% lower over the past year. These moves have kept Equifax in focus for investors who follow business services names and are weighing how...

Virgin Galactic Holdings recently filed a US$1.35 million shelf registration for 555,000 shares tied to its employee stock plan and reported fourth-quarter 2025 sales of US$312,000 alongside a net loss of US$62.72 million. At the same time, the company has reopened US$750,000-per-seat ticket sales and advanced its Delta-class spacecraft toward testing, highlighting a push to align capital, talent and product readiness ahead of a planned return to commercial service. We’ll now examine how the...

Insmed announced that its Phase 2b CEDAR study of brensocatib in adults with moderate to severe hidradenitis suppurativa failed to meet primary or secondary efficacy endpoints, leading the company to halt development of the drug for this indication despite a clean safety profile. An interesting outcome was that placebo patients saw a larger reduction in abscess and inflammatory nodule counts than either brensocatib dose, raising fresh questions about disease variability and trial design in...

Recent bearish coverage around Pfizer (PFE), including a reiterated Underperform rating and concerns about weaker revenue from key products, has weighed on sentiment. At the same time, a paused COVID-19 vaccine trial adds to short term uncertainty. See our latest analysis for Pfizer. Despite the latest bearish commentary and trial pause weighing on sentiment in recent days, Pfizer’s share price shows a 9.1% year to date share price return and a 31.0% total shareholder return over the past...